BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9785331)

  • 1. Quality of life in clinical trials: assessment and utility with special reference to rHuEPO.
    Brandberg Y
    Med Oncol; 1998 Aug; 15 Suppl 1():S8-12. PubMed ID: 9785331
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand.
    Roungrong J; Teerawattananon Y; Chaikledkaew U
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S119-25. PubMed ID: 19255987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?
    Osterborg A
    Med Oncol; 1998 Aug; 15 Suppl 1():S47-9. PubMed ID: 9785337
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing the impact of cancer-related anaemia on quality of life and the role of rHuEPO.
    Brandberg Y
    Med Oncol; 2000 Nov; 17 Suppl 1():S23-31. PubMed ID: 11188783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rHuEPO and improved treatment outcomes: potential modes of action.
    Blackwell K; Gascón P; Sigounas G; Jolliffe L
    Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical use of erythropoietin].
    Franchini M; Gandini G; Lippi G; De Gironcoli M; Cantini M; Aprili G
    Recenti Prog Med; 2004 Mar; 95(3):129-36; quiz 185. PubMed ID: 15143948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alfa-epoietin and anaemia in gynaecological cancer.
    Di Cocco B; Salesi N; Fabi A; Nardoni C; Ferretti G; Bossone G; Ciccarese M; Savarese A; Vecchione A; Cognetti F
    Anticancer Res; 2004; 24(2C):1287-92. PubMed ID: 15154662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin in clinical practice: current use, effect on survival, and future directions.
    Oster HS; Hoffman M; Prutchi-Sagiv S; Katz O; Neumann D; Mittelman M
    Isr Med Assoc J; 2006 Oct; 8(10):703-6. PubMed ID: 17125118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NCCN: New applications for erythropoietin.
    Demetri GD
    Cancer Control; 2001; 8(6 Suppl 2):72-6. PubMed ID: 11760562
    [No Abstract]   [Full Text] [Related]  

  • 10. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].
    Lastiri JM; Specterman SR; Rendo P; Pallotta MG; Varela MS; Goldstein S
    Medicina (B Aires); 2002; 62(1):41-7. PubMed ID: 11965849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
    Baron F; Frère P; Fillet G; Beguin Y
    Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of recombinant human erythropoietin in the management of anaemic cancer patients: focus on haematological malignancies.
    Osterbor A
    Med Oncol; 2000 Nov; 17 Suppl 1():S17-22. PubMed ID: 11188781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current thinking and treatment practices in anaemia--an interactive poll.
    Spivak JL; Cazzola M
    Med Oncol; 2000 Nov; 17 Suppl 1():S32-7. PubMed ID: 11188784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy.
    Hedenus M; Näsman P; Liwing J
    J Clin Pharm Ther; 2008 Aug; 33(4):365-74. PubMed ID: 18613854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of human recombinant erythropoietin in children with cancer].
    Guyot D; Margueritte G
    Arch Pediatr; 2005 Sep; 12(9):1376-82. PubMed ID: 16084072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous iron and recombinant human erythropoietin in cancer patients.
    Beguin Y
    J Clin Oncol; 2005 Jan; 23(3):651-2; author reply 652-3. PubMed ID: 15659518
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant human erythropoietin in the treatment of nonrenal anemia.
    Heuser M; Ganser A
    Ann Hematol; 2006 Feb; 85(2):69-78. PubMed ID: 16078035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin therapy: need for rationality and active surveillance.
    Cazzola M
    Haematologica; 2003 Jun; 88(6):601-5. PubMed ID: 12801832
    [No Abstract]   [Full Text] [Related]  

  • 19. Guidelines for the use of rHuEpo in anaemia of malignancy. Department of Internal Medicine and Medical Therapy, University of Pavia Medical school, Pavia, Italy.
    Med Oncol; 1998 Aug; 15 Suppl 1():S50. PubMed ID: 9785338
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin.
    Cazzola M
    Med Oncol; 2000 Nov; 17 Suppl 1():S11-6. PubMed ID: 11188780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.